RE:RE:RE:30 million for breast cancer trialRepeatedly having to be restated - ONCY'S patents do nor run out until 2031 and an FDA approval would grant pelareorep 13 years of exclusivity from the date of approval for each indication the pelareorep is granted. The rest of the stuff is just a disquieting rant by someone who doesn't own any shares in the company.